UCL 1684 (dibromide)

UCL 1684 (dibromide) is a first nanomolar, non-peptidic small conductance calcium-activated potassium (SK) channel blocker. UCL 1684 (dibromide) is effective in preventing the development of atrial fibrillation due to potent atrial-selective inhibition of INa. UCL 1684 (dibromide) causes atrial-selective prolongation of ERP secondary to induction of postrepolarization refractoriness[1][2][3].

Product Specifications

CAS Number

[199934-16-2]

UNSPSC

12352005

Target

Potassium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/ucl-1684-dibromide.html

Purity

98.07

Solubility

DMSO : 5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

C12=[N+](CC3=CC(C[N+]4=CC=C(NCC5=CC=C(C=C5)CN6)C7=CC=CC=C47)=CC=C3)C=CC6=C1C=CC=C2.[Br-].[Br-]

Molecular Formula

C34H30Br2N4

Molecular Weight

654.44

References & Citations

[1]Burashnikov A, et al. The Small Conductance Calcium-Activated Potassium Channel Inhibitors NS8593 and UCL1684 Prevent the Development of Atrial Fibrillation Through Atrial-Selective Inhibition of Sodium Channel Activity. J Cardiovasc Pharmacol. 2020;76 (2) :164-172.|[2]Rosa JC, et al. Bis-quinolinium cyclophanes: 6,10-diaza-3 (1,3),8 (1,4) -dibenzena-1,5 (1,4) - diquinolinacyclodecaphane (UCL 1684), the first nanomolar, non-peptidic blocker of the apamin-sensitive Ca (2+) -activated K+ channel. J Med Chem. 1998;41 (1) :2-5.|[3]Diness JG, et al. Effects on atrial fibrillation in aged hypertensive rats by Ca (2+) -activated K (+) channel inhibition. Hypertension. 2011;57 (6) :1129-1135.